BUZZ-TransMedics drops as Q3 revenue misses analyst estimates

Reuters10-30

** Shares of medtech company TransMedics TMDX.O fall 7% to $123.98 premarket after Q3 revenue miss

** Co posts Q3 rev of $143.8 mln

** Co says revenue grew 32% YoY, driven by increased utilization of the Organ Care System, particularly in Liver and Heart through National OCS Program — but missed analyst estimates of $145.2 mln

** TMDX reported 3Q rev of $143.8 mln, 0.5% below cons of $144.6 mln, as anticipated seasonality impact materialized - Jefferies analysts

** TMDX raises 2025 revenue guidance to $595 mln-$605 mln

** Co announces collaboration with Mercedes-Benz for organ transport in Italy

** 10 out of 13 analysts rate stock "buy" or higher, three "hold"; the median PT at $147.50 - data compiled by LSEG

** TMDX stock UP 115.43% YTD, as of last close

(Reporting by Tharuniyaa Lakshmi in Bengaluru)

((tharuniyaa@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2579114091?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-30 18:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2579114091","market":"fut","top_or_hot":-1,"title":"BUZZ-TransMedics drops as Q3 revenue misses analyst estimates","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-TransMedics drops as Q3 revenue misses analyst estimates</title></head><body><p>** Shares of medtech company TransMedics <span>TMDX.O</span> fall 7% to $123.98 premarket after <span>Q3 revenue</span> miss </p><p>** Co posts Q3 rev of $143.8 mln</p><p>** Co says revenue grew 32% YoY, driven by increased utilization of the Organ Care System, particularly in Liver and Heart through National OCS Program — but missed analyst estimates of $145.2 mln</p><p>** TMDX reported 3Q rev of $143.8 mln, 0.5% below cons of $144.6 mln, as anticipated seasonality impact materialized - Jefferies analysts</p><p>** TMDX raises 2025 revenue guidance to $595 mln-$605 mln</p><p>** Co announces collaboration with Mercedes-Benz for organ transport in Italy</p><p>** 10 out of 13 analysts rate stock \"buy\" or higher, three \"hold\"; the median PT at $147.50 - data compiled by LSEG </p><p>** TMDX stock UP 115.43% YTD, as of last close</p><p> (Reporting by Tharuniyaa Lakshmi in Bengaluru)</p><p> ((tharuniyaa@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-TransMedics drops as Q3 revenue misses analyst estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-TransMedics drops as Q3 revenue misses analyst estimates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-30 18:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-TransMedics drops as Q3 revenue misses analyst estimates</title></head><body><p>** Shares of medtech company TransMedics <span>TMDX.O</span> fall 7% to $123.98 premarket after <span>Q3 revenue</span> miss </p><p>** Co posts Q3 rev of $143.8 mln</p><p>** Co says revenue grew 32% YoY, driven by increased utilization of the Organ Care System, particularly in Liver and Heart through National OCS Program — but missed analyst estimates of $145.2 mln</p><p>** TMDX reported 3Q rev of $143.8 mln, 0.5% below cons of $144.6 mln, as anticipated seasonality impact materialized - Jefferies analysts</p><p>** TMDX raises 2025 revenue guidance to $595 mln-$605 mln</p><p>** Co announces collaboration with Mercedes-Benz for organ transport in Italy</p><p>** 10 out of 13 analysts rate stock \"buy\" or higher, three \"hold\"; the median PT at $147.50 - data compiled by LSEG </p><p>** TMDX stock UP 115.43% YTD, as of last close</p><p> (Reporting by Tharuniyaa Lakshmi in Bengaluru)</p><p> ((tharuniyaa@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251030:nL6N3WB0NC:1","article_id":"2579114091","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2579114091","pubTimestamp":1761821392,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-TransMedics drops as Q3 revenue misses analyst estimates** Shares of medtech company TransMedics TMDX.O fall 7% to $123.98 premarket after Q3 revenue miss ** Co posts Q3 rev of $143.8 mln** Co says revenue grew 32% YoY, driven by increased utilization of the Organ Care System, particularly in Liver and Heart through National OCS Program — but missed analyst estimates of $145.2 mln** TMDX reported 3Q rev of $143.8 mln, 0.5% below cons of $144.6 mln, as anticipated seasonality impact materialized - Jefferies analysts** TMDX raises 2025 revenue guidance to $595 mln-$605 mln** Co announces collaboration with Mercedes-Benz for organ transport in Italy** 10 out of 13 analysts rate stock \"buy\" or higher, three \"hold\"; the median PT at $147.50 - data compiled by LSEG ** TMDX stock UP 115.43% YTD, as of last close  ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","LU2065731478.USD":"ALLSPRING (LUX) WORLDWIDE FUND - SMALL CAP INNOVA \"I\" (USD) ACC","BK4082":"医疗保健设备","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","TMDX":"TransMedics Group Inc.","BK4588":"碎股"},"translate_title":"BUZZ-TransMedics第三季度收入低于分析师预期，股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TMDX":0.9},"content_text":"BUZZ-TransMedics drops as Q3 revenue misses analyst estimates** Shares of medtech company TransMedics TMDX.O fall 7% to $123.98 premarket after Q3 revenue miss ** Co posts Q3 rev of $143.8 mln** Co says revenue grew 32% YoY, driven by increased utilization of the Organ Care System, particularly in Liver and Heart through National OCS Program — but missed analyst estimates of $145.2 mln** TMDX reported 3Q rev of $143.8 mln, 0.5% below cons of $144.6 mln, as anticipated seasonality impact materialized - Jefferies analysts** TMDX raises 2025 revenue guidance to $595 mln-$605 mln** Co announces collaboration with Mercedes-Benz for organ transport in Italy** 10 out of 13 analysts rate stock \"buy\" or higher, three \"hold\"; the median PT at $147.50 - data compiled by LSEG ** TMDX stock UP 115.43% YTD, as of last close (Reporting by Tharuniyaa Lakshmi in Bengaluru) ((tharuniyaa@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2579114091","isCrawlerRequest":true}